2017 American Society of Clinical Oncology Annual Meeting*

Download All
June 2-6, 2017; Chicago, Illinois
Steven J. Cohen, MD, and Alan P. Venook, MD, review and share their expert perspectives on key GI cancer findings presented at the 2017 American Society of Clinical Oncology Annual Meeting.
Steven J. Cohen, MD
Alan P. Venook, MD

Gastrointestinal Cancers

In these subanalyses of the CALGB/SWOG 80405 trial, tumor sidedness was a prognostic factor independent of other molecular features, and BRAF status was also a strong prognostic marker for patients with mCRC receiving first-line treatment.

Released: June 14, 2017

In this open-label phase II study, addition of vemurafenib associated with significantly improved PFS and clinical activity in BRAF V600E mCRC patients previously treated with systemic chemotherapy.

Released: June 12, 2017

Next-generation sequencing of circulating tumor DNA revealed complex mutational changes with panitumumab treatment.

Released: June 8, 2017

Lenvatinib demonstrated noninferior OS, significantly increased PFS, TTP, and ORR vs sorafenib with expected safety profile.

Released: June 5, 2017

No significant difference in OS noted, but patients in treated population who received SIRT experienced higher ORR and fewer AEs/serious AEs vs those who received sorafenib.

Released: June 7, 2017

Pembrolizumab well tolerated, produced durable responses in patients with pretreated, advanced gastric/GEJ cancer, with highest responses in PD-L1–positive subgroup.

Released: June 13, 2017

In this trial, adjuvant capecitabine improved survival vs placebo in patients with resected biliary cancer with modest toxicity and no reduction in quality of life.

Released: June 7, 2017

Addition of PEGPH20 to nab-paclitaxel/gemcitabine improved PFS in the full study population with the greatest improvement in the patients with high tumor levels of hyaluronan.

Released: June 6, 2017

AG-120 was associated with fatigue and gastrointestinal toxicities and prolonged stable disease.

Released: June 6, 2017

In this text module and accompanying downloadable slideset, experts Steven J. Cohen, MD, and Alan P. Venook, MD, review the most clinically relevant study results presented at Clinical Oncology 2017 in colorectal cancer, hepatocellular cancer, gastric cancers, biliary cancers, and pancreatic cancer.

Steven J. Cohen, MD Alan P. Venook, MD Physicians: maximum of 1.0 AMA PRA Category 1 Credit Released: August 7, 2017 Expired: No longer available for credit

In this analysis of 6 phase III trials, DFS and neuropathy rates varied with adjuvant oxaliplatin duration among patients based on risk factors and regimen.

Released: June 5, 2017
Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants by
Celgene Corporation
Halozyme Therapeutics
Merck & Co., Inc.

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.